<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199939</url>
  </required_header>
  <id_info>
    <org_study_id>CR017149</org_study_id>
    <secondary_id>TMC125HIV4007</secondary_id>
    <nct_id>NCT01199939</nct_id>
  </id_info>
  <brief_title>A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients</brief_title>
  <acronym>INROADS</acronym>
  <official_title>A Multicenter, Single Arm, Open-Label Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tibotec, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase II single arm, open-label, multicenter, study of 50 human
      immunodeficiency virus-1 (HIV) infected adult patients, all of whom will receive etravirine
      (ETR) 400mg and DRV/r 800/100mg each given orally once daily. This trial is designed to
      evaluate the efficacy of the aforementioned ARV regimen, as measured by the percentage of
      patients with HIV RNA &lt;50 copies/mL at 48 weeks, in early treatment-experienced HIV-infected
      patients. In addition to general safety parameter measurements, this trial will also assess
      changes in metabolic, inflammatory, immune restoration, and bone markers. Screening will
      occur over a 6-week period. The primary endpoint will be assessed at Week 48, and the
      treatment period is 48 weeks. The end of study endpoint will be met by either completing the
      Week 48 visit, or by early termination from the study for any reason.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase II single arm, open-label, multicenter, (all people involved know the
      identity of the intervention) study of 50 HIV-1 infected adult patients, all of whom will
      receive ETR 400mg and darunavir (DRV)/r 800/100mg each given orally once daily. This trial is
      designed to evaluate the efficacy of the aforementioned ARV regimen, as measured by the
      percentage of patients with HIV ribonucleic acid (RNA) &lt;50 copies/mL at 48 weeks, in early
      treatment-experienced HIV-infected patients. In addition to general safety parameter
      measurements, this trial will also assess changes in metabolic, inflammatory, immune
      restoration, and bone markers. Screening will occur over a 6-week period. The trial schedule
      includes a Baseline Visit (Day 1), Open-label Treatment Phase (Weeks 4, 8, 12, 16, 20, 24,
      30, 36, 42, 48/ Early Withdrawal) and a Post-treatment Phase (4 Week Follow-Up) visit. In
      addition, all patients will have two pharmacokinetic (PK) samples drawn at Weeks 4 and 24, A
      single PK sample will be drawn at Weeks 12, 36, and 48 (or early withdrawal visit). There
      will also be a substudy conducting 24 hour intensive PK at week 4 for a subset of patients.
      For patients who consent, genotyping for CYP2C9 and CYP2C19 will be performed at Baseline. A
      Modified Medication Adherence Self-Report Inventory (M-MASRI) questionnaire will be
      collected, which is a patient-reported survey to assess adherence to medication taking. The
      primary endpoint will be assessed at Week 48, and the treatment period is 48 weeks. The end
      of study endpoint will be met by either completing the Week 48 visit, or by early termination
      from the study for any reason. ETR 400mg once daily for 48 weeks and DRV 800mg once daily for
      48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Confirmed Virologic Response (CVR) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus - type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 4</measure>
    <time_frame>Baseline (Day 1) and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 8</measure>
    <time_frame>Baseline (Day 1) and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 16</measure>
    <time_frame>Baseline (Day 1) and Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 20</measure>
    <time_frame>Baseline (Day 1) and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 24</measure>
    <time_frame>Baseline (Day 1) and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 30</measure>
    <time_frame>Baseline (Day 1) and Week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 36</measure>
    <time_frame>Baseline (Day 1) and Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 42</measure>
    <time_frame>Baseline (Day 1) and Week 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 48</measure>
    <time_frame>Baseline (Day 1) and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach First Confirmed Virologic Response</measure>
    <time_frame>Baseline (Day 1) to Week 48</time_frame>
    <description>CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus - type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virologic Failure</measure>
    <time_frame>Baseline (Day 1) to Week 48</time_frame>
    <description>Virologic Failure is defined as participant who is a rebounder or a non-responder. Rebounder participant is defined as a participant who is still in the study at Week 12 and first achieves 2 consecutive virologic responses (&lt;50 copies/mL) followed by 2 consecutive non-responses or a discontinued participant (any reason) for which the last observed time point shows a non-response. Non responder participant is defined as a participant who is still in the study at Week 12 and never achieves 2 consecutive responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48</measure>
    <time_frame>Baseline (Day 1) and Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>ETR + DRV/rtv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine</intervention_name>
    <description>400mg once daily orally for 48 weeks</description>
    <arm_group_label>ETR + DRV/rtv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100mg once daily orally for 48 weeks</description>
    <arm_group_label>ETR + DRV/rtv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>800mg once daily orally for 48 weeks</description>
    <arm_group_label>ETR + DRV/rtv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, aged 18 years or above

          -  Patients with documented HIV-1 infection

          -  On current HAART regimen for at least 12 weeks continuous duration at screening, and
             with an HIV-1 plasma viral load above 500 HIV-1 RNA copies/mL by site's currently
             utilized viral load assay (Note: For the purposes of this study, HAART is defined as
             treatment with a combination of 3 or more HIV antiretroviral medications from at least
             2 different classes of medications (NRTIs, NNRTIs, PIs, integrase inhibitors, CCR5
             antagonists, fusion inhibitors))

          -  No more than 2 previous virologic failures while on PI-containing HAART regimens where
             virologic failure is generally defined as either a lack of suppression of the
             subjects' viral load to lower limit of quantification (per standard assay historically
             used in care) after 24 weeks of treatment or, rebound of a previously suppressed viral
             load (undetectable per investigator's standard of care) to detectable limits and
             without demonstrated re-suppression on the same regimen

          -  Demonstrated phenotypic sensitivity to both etravirine and darunavir based on
             resistance testing at Screening (FC= 2.9 for etravirine and FC = 10.0 for darunavir
             using the PhenoSense GT)

          -  The absence of all of the following Resistance Associated Mutations (RAMS) at
             baseline: For Darunavir: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V

          -  For Etravirine: L100I, E138A, I167V, V179D, V179F, Y181I, Y181V, G190S

          -  7. CD4 count = 50 cells/mm3.

        Exclusion Criteria:

          -  Primary HIV-1 infection

          -  Previously documented HIV-2 infection

          -  Use of disallowed concomitant therapy

        Any condition (including but not limited to alcohol and drug use), which, in the opinion of
        the investigator, could compromise the patient's safety or adherence to the protocol

          -  Life expectancy less than 6 months according to the judgment of the investigator

          -  Patient has any currently active AIDS defining illness (Category C conditions
             according to the Center for Disease Control [CDC] Classification System for HIV
             infection 1993

          -  with the following exceptions, which must be discussed with the sponsor prior to
             enrollment: Stable cutaneous Kaposi's Sarcoma (i.e., no pulmonary or gastrointestinal
             involvement other than oral lesions) that is unlikely to require any form of systemic
             therapy during the trial period

          -  Wasting syndrome due to HIV infection if, in the investigator's opinion, it is not
             actively progressive and its treatment does not require hospitalization or compromise
             the patient's safety or compliance to adhere to trial-related procedures. If the
             patient is on maintenance therapy (which may include Growth Hormone, appetite
             stimulants and anabolic steroids) for previously diagnosed wasting syndrome, he/she
             may be eligible for the trial. Note: An AIDS defining illness not clinically
             stabilized for at least 30 days will be considered clinically active. Note: Primary
             and secondary prophylaxis for an AIDS defining illness is allowed in case the
             medication used is not part of the disallowed medications

          -  Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or
             findings during screening of medical history, laboratory or physical examination that,
             in the investigator's opinion, would compromise the patient's safety or the outcome of
             the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <results_first_submitted>October 4, 2013</results_first_submitted>
  <results_first_submitted_qc>October 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2013</results_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>HIV</keyword>
  <keyword>Etravirine</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Prezista</keyword>
  <keyword>Intelence</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>INROADS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between 29 March 2010 and 5 October 2012 and recruited patients from US (17 sites) and Puerto Rico (1 site).</recruitment_details>
      <pre_assignment_details>54 participants were treated with Etravirine and Darunavir/ritonavir in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ETR + DRV/Rtv</title>
          <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54">Number of enrolled participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reached a virologic endpoint</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ETR + DRV/Rtv</title>
          <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Confirmed Virologic Response (CVR) at Week 48</title>
        <description>CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus – type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.</description>
        <time_frame>Week 48</time_frame>
        <population>Intent-To-Treat Non-Virologic failure (VF) censored: Participants who took at least one dose of any of the study medications and did not withdraw for reasons other than VF or experienced VF prior to discontinuation. Participants with evaluable data at Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Confirmed Virologic Response (CVR) at Week 48</title>
          <description>CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus – type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.</description>
          <population>Intent-To-Treat Non-Virologic failure (VF) censored: Participants who took at least one dose of any of the study medications and did not withdraw for reasons other than VF or experienced VF prior to discontinuation. Participants with evaluable data at Week 48</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 4</title>
        <time_frame>Baseline (Day 1) and Week 4</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 4</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 4</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" lower_limit="-3.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 8</title>
        <time_frame>Baseline (Day 1) and Week 8</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 8</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 8</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 8</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" lower_limit="-3.3" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 12</title>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 12</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 12</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" lower_limit="-3.6" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 16</title>
        <time_frame>Baseline (Day 1) and Week 16</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 16</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 16</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" lower_limit="-4.0" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 20</title>
        <time_frame>Baseline (Day 1) and Week 20</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 20</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 20</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 20</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" lower_limit="-4.0" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 24</title>
        <time_frame>Baseline (Day 1) and Week 24</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 24</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 24</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" lower_limit="-3.9" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 30</title>
        <time_frame>Baseline (Day 1) and Week 30</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 30</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 30</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 30</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" lower_limit="-4.0" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 36</title>
        <time_frame>Baseline (Day 1) and Week 36</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 36</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 36</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 36</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" lower_limit="-3.9" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 42</title>
        <time_frame>Baseline (Day 1) and Week 42</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 42</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 42</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 42</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" lower_limit="-3.9" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 48</title>
        <time_frame>Baseline (Day 1) and Week 48</time_frame>
        <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10 Plasma Human Immunodeficiency Virus – Type 1 (HIV-1) Viral Load at Week 48</title>
          <population>Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 48</population>
          <units>log10 Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" lower_limit="-3.9" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach First Confirmed Virologic Response</title>
        <description>CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus – type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.</description>
        <time_frame>Baseline (Day 1) to Week 48</time_frame>
        <population>Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach First Confirmed Virologic Response</title>
          <description>CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus – type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.</description>
          <population>Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.98" spread="6.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virologic Failure</title>
        <description>Virologic Failure is defined as participant who is a rebounder or a non-responder. Rebounder participant is defined as a participant who is still in the study at Week 12 and first achieves 2 consecutive virologic responses (&lt;50 copies/mL) followed by 2 consecutive non-responses or a discontinued participant (any reason) for which the last observed time point shows a non-response. Non responder participant is defined as a participant who is still in the study at Week 12 and never achieves 2 consecutive responses.</description>
        <time_frame>Baseline (Day 1) to Week 48</time_frame>
        <population>Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virologic Failure</title>
          <description>Virologic Failure is defined as participant who is a rebounder or a non-responder. Rebounder participant is defined as a participant who is still in the study at Week 12 and first achieves 2 consecutive virologic responses (&lt;50 copies/mL) followed by 2 consecutive non-responses or a discontinued participant (any reason) for which the last observed time point shows a non-response. Non responder participant is defined as a participant who is still in the study at Week 12 and never achieves 2 consecutive responses.</description>
          <population>Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="6.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48</title>
        <time_frame>Baseline (Day 1) and Week 48</time_frame>
        <population>Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications</population>
        <group_list>
          <group group_id="O1">
            <title>ETR + DRV/Rtv</title>
            <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48</title>
          <population>Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="153.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69" spread="289.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ETR + DRV/Rtv</title>
          <description>Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hodgkin's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fibrin D Dimer Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Low Density Lipoprotein Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SENIOR MEDICAL DIRECTOR</name_or_title>
      <organization>Janssen Pharmaceuticals</organization>
      <phone>1 609 730-2931</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

